GlassScriptPhysician profile
John H Slaughter
NPI 1962618900
$1,798.89
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,587 · 2022: $212.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $166.16 | 2021-2022 | |
| Daiichi Sankyo INC. | $156.40 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $139.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.14 | 2021 | |
| Amgen INC. | $95.25 | 2021 | |
| Seagen INC. | $79.17 | 2021 | |
| Beigene USA, INC. | $76.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.32 | 2021 | |
| Kite Pharma, INC. | $70.84 | 2021-2022 | |
| Dova Pharmaceuticals | $66.56 | 2021 | |
| Janssen Biotech, INC. | $58.99 | 2021 | |
| Pfizer INC. | $55.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.06 | 2021-2022 | |
| Puma Biotechnology, INC. | $49.31 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $42.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.99 | 2022 | |
| Astellas Pharma US INC | $40.05 | 2021 | |
| Lilly USA, LLC | $35.24 | 2021-2022 | |
| Sobi, INC | $30.21 | 2022 | |
| Karyopharm Therapeutics INC. | $27.72 | 2021 | |
| Exelixis INC. | $26.30 | 2021 | |
| Acrotech Biopharma INC. | $22.96 | 2022 | |
| Heron Therapeutics, INC. | $21.28 | 2021 | |
| Glaxosmithkline, LLC. | $19.44 | 2021 | |
| Eisai INC. | $18.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.98 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.